Drug-drug interaction between bosutinib and warfarin. 2014

Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
Division of Hematology, Mayo Clinic , Rochester, MN , USA.

UI MeSH Term Description Entries
D008297 Male Males
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011804 Quinolines
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000814 Aniline Compounds Compounds that include the aminobenzene structure. Phenylamine,Phenylamines,Anilines,Compounds, Aniline
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D013921 Thrombocytopenia A subnormal level of BLOOD PLATELETS. Thrombopenia,Thrombocytopenias,Thrombopenias
D014859 Warfarin An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one,Aldocumar,Apo-Warfarin,Coumadin,Coumadine,Gen-Warfarin,Marevan,Tedicumar,Warfant,Warfarin Potassium,Warfarin Sodium,Potassium, Warfarin,Sodium, Warfarin

Related Publications

Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
April 1988, The New Zealand medical journal,
Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
August 2005, Japanese journal of clinical oncology,
Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
November 2018, Therapeutic advances in drug safety,
Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
September 1979, American journal of hospital pharmacy,
Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
January 2015, Internal medicine (Tokyo, Japan),
Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
December 2009, The Annals of pharmacotherapy,
Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
January 2016, Gan to kagaku ryoho. Cancer & chemotherapy,
Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
June 2024, Hospital pharmacy,
Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
February 2021, British journal of clinical pharmacology,
Ashish V Chintakuntlawar, and Heidi D Finnes, and Ayalew Tefferi, and Animesh Pardanani
December 2015, Pharmacoepidemiology and drug safety,
Copied contents to your clipboard!